We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Australia Health Care Company Prima Biomed Ltd Enters Agreement with Fraunhofer Institute for Cell Therapy and Immunology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Australia Health Care Company Prima Biomed Ltd Enters Agreement with Fraunhofer Institute for Cell Therapy and Immunology"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The preparation for production of CVac™ for the European trial has
already commenced, and Prima BioMed Ltd and the Fraunhofer IZI are
working together to prepare the facility to support CVac™ clinical trials
in Europe in early 2011. This represents a significant milestone on the
pathway to commercialisation of CVac™ in the European market.
In addition the agreement with Fraunhofer provides a number of other
key benefits to Prima BioMed Ltd. Fraunhofer is among the foremost
R&D institutes in Europe and it has strong collaborative networks
throughout academia, government, and industry. Fraunhofer will help
enhance the visibility of the CVac™ clinical program in Europe and

Prima Chief Operating Officer and Managing Director for Europe, Matthew
Lehman said: “The Fraunhofer Institute is among the foremost
research and development organisations in the world and Prima is
delighted to enter into this collaborative arrangement (…)”. Fraunhofer
IZI Head of Cell Therapy Production, Dr. Gerno Schmiedeknecht, commented:

“Cell therapies are a cutting-edge technology with the potential
to significantly benefit patients. The Fraunhofer IZI is at the forefront
of this technology in Europe and we are very excited to help develop
Prima’s CVac™.”